Causes of death among women with human immunodeficiency virus infection in the era of combination antiretroviral therapy
- PMID: 12133746
- PMCID: PMC3126666
- DOI: 10.1016/s0002-9343(02)01169-5
Causes of death among women with human immunodeficiency virus infection in the era of combination antiretroviral therapy
Abstract
Purpose: To examine changes in the causes of death and mortality in women with human immunodeficiency virus (HIV) infection in the era of combination antiretroviral therapy.
Methods: Among women with, or at risk of, HIV infection, who were enrolled in a national study from 1994 to 1995, we used an algorithm that classified cause of death as due to acquired immunodeficiency syndrome (AIDS) or non-AIDS causes based on data from death certificates and the CD4 count. Poisson regression models were used to estimate death rates and to determine the risk factors for AIDS and non-AIDS deaths.
Results: Of 2059 HIV-infected women and 569 who were at risk of HIV infection, 468 (18%) had died by April 2000 (451 HIV-infected and 17 not infected). Causes of death were available for 428 participants (414 HIV-infected and 14 not infected). Among HIV-infected women, deaths were classified as AIDS (n = 294), non-AIDS (n = 91), or indeterminate (n = 29). The non-AIDS causes included liver failure (n = 19), drug overdose (n = 16), non-AIDS malignancies (n = 12), cardiac disease (n = 10), and murder, suicide, or accident (n = 10). All-cause mortality declined an average of 26% per year (P = 0.03) and AIDS-related mortality declined by 39% per year (P = 0.01), whereas non-AIDS-related mortality remained stable (10% average annual decrease, P = 0.73). Factors that were independently associated with non-AIDS-related mortality included depression, history of injection drug use with hepatitis C infection, cigarette smoking, and age.
Conclusion: A substantial minority (20%) of deaths among women with HIV was due to causes other than AIDS. Our data suggest that to decrease mortality further among HIV-infected women, attention must be paid to treatable conditions, such as hepatitis C, depression, and drug and tobacco use.
Figures
Similar articles
-
Cause-specific life expectancies after 35 years of age for human immunodeficiency syndrome-infected and human immunodeficiency syndrome-negative individuals followed simultaneously in long-term cohort studies, 1984-2008.Am J Epidemiol. 2013 Jan 15;177(2):116-25. doi: 10.1093/aje/kws321. Epub 2013 Jan 3. Am J Epidemiol. 2013. PMID: 23287403 Free PMC article.
-
Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 to 2003.HIV Med. 2005 Mar;6(2):99-106. doi: 10.1111/j.1468-1293.2005.00271.x. HIV Med. 2005. PMID: 15807715
-
Ten-year mortality trends among persons diagnosed with HIV infection in England and Wales in the era of antiretroviral therapy: AIDS remains a silent killer.HIV Med. 2013 Nov;14(10):596-604. doi: 10.1111/hiv.12045. Epub 2013 May 15. HIV Med. 2013. PMID: 23672663
-
Human immunodeficiency virus infection, Part I.Dis Mon. 1998 Oct;44(10):545-606. doi: 10.1016/s0011-5029(98)90014-1. Dis Mon. 1998. PMID: 9814367 Review.
-
Human immunodeficiency virus in an aging population, a complication of success.J Am Geriatr Soc. 2009 Nov;57(11):2129-38. doi: 10.1111/j.1532-5415.2009.02494.x. Epub 2009 Sep 28. J Am Geriatr Soc. 2009. PMID: 19793157 Review.
Cited by
-
Cause-specific life expectancies after 35 years of age for human immunodeficiency syndrome-infected and human immunodeficiency syndrome-negative individuals followed simultaneously in long-term cohort studies, 1984-2008.Am J Epidemiol. 2013 Jan 15;177(2):116-25. doi: 10.1093/aje/kws321. Epub 2013 Jan 3. Am J Epidemiol. 2013. PMID: 23287403 Free PMC article.
-
Relationship between food insecurity and mortality among HIV-positive injection drug users receiving antiretroviral therapy in British Columbia, Canada.PLoS One. 2013 May 27;8(5):e61277. doi: 10.1371/journal.pone.0061277. Print 2013. PLoS One. 2013. PMID: 23723968 Free PMC article.
-
Systematic review and meta-analysis on the effect of depression on ART adherence among women living with HIV.PLoS One. 2024 Jun 20;19(6):e0300106. doi: 10.1371/journal.pone.0300106. eCollection 2024. PLoS One. 2024. PMID: 38900748 Free PMC article.
-
CYP1A1 genotype modifies the impact of smoking on effectiveness of HAART among women.AIDS Educ Prev. 2009 Jun;21(3 Suppl):81-93. doi: 10.1521/aeap.2009.21.3_supp.81. AIDS Educ Prev. 2009. PMID: 19537956 Free PMC article.
-
The impact of kidney function at highly active antiretroviral therapy initiation on mortality in HIV-infected women.J Acquir Immune Defic Syndr. 2010 Oct;55(2):217-20. doi: 10.1097/QAI.0b013e3181e674f4. J Acquir Immune Defic Syndr. 2010. PMID: 20581688 Free PMC article.
References
-
- Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report. Atlanta, Georgia: U.S. Department of Health and Human Services, CDC; 2000.
-
- Palella FJ, Delaney KM, Moorman A, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;339:853–860. - PubMed
-
- McNaghten AD, Hanson DL, Jones JL, et al. Effects of antiretroviral therapy and opportunistic illness primary chemoprophylaxis on survival after AIDS diagnosis. Adult/Adolescent Spectrum of Disease Group. AIDS. 1999;13:1687–1695. - PubMed
-
- Whitman S, Murphy J, Cohen M, Sherer R. Marked declines in human immunodeficiency virus-related mortality in Chicago in women, African Americans, Hispanics, young adults and injection drug users, from 1995–1997. Arch Intern Med. 2000;160:365–369. - PubMed
-
- Anderson K, Mitchell J. Differential access in the receipt of antiretroviral drugs for the treatment of AIDS and its implications for survival. Arch Intern Med. 2000;160:3114 –3120. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- U01 AI031834/AI/NIAID NIH HHS/United States
- U01 AI035004/AI/NIAID NIH HHS/United States
- RR00083/RR/NCRR NIH HHS/United States
- HD-32632/HD/NICHD NIH HHS/United States
- M01 RR000071/RR/NCRR NIH HHS/United States
- AI-35004/AI/NIAID NIH HHS/United States
- RR00071/RR/NCRR NIH HHS/United States
- AI-42590/AI/NIAID NIH HHS/United States
- AI-34993/AI/NIAID NIH HHS/United States
- U01 AI034993/AI/NIAID NIH HHS/United States
- M01 RR000083/RR/NCRR NIH HHS/United States
- AI-34994/AI/NIAID NIH HHS/United States
- R56 AI052065/AI/NIAID NIH HHS/United States
- U01 AI034989/AI/NIAID NIH HHS/United States
- R01 AI052065/AI/NIAID NIH HHS/United States
- AI-31834/AI/NIAID NIH HHS/United States
- AI-34989/AI/NIAID NIH HHS/United States
- U01 AI034994/AI/NIAID NIH HHS/United States
- U01 HD032632/HD/NICHD NIH HHS/United States
- U01 AI042590/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous